SCHEMBL436359

SCHEMBL436359

Cc1ccc(-c2nc3ccc(C)cn3c2C(O)C(=O)N(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.58
GABRB2 P47870 4/20 0.58
KDM4E B2RXH2 3/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 2/20 0.58
LMNA P02545 1/20 0.58
ALB P02768 1/20 0.58
CYP3A4 P08684 1/20 0.58
CHRM1 P11229 1/20 0.58
GABRB1 P18505 1/20 0.58
GABRG2 P18507 1/20 0.58
GABRB3 P28472 1/20 0.58
GABRA3 P34903 1/20 0.58
ADRA1A P35348 1/20 0.58
OPRK1 P41145 1/20 0.58
HTR2B P41595 1/20 0.58
GABRA2 P47869 1/20 0.58
KCNH2 Q12809 1/20 0.58
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10120369 0.93 GABRA1 (0.51) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL5253722 0.86 KDM4E (0.52) GABRA1GABRB2KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL10614798 0.85 GABRA1 (0.56) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL10527021 0.79 TSPO (0.48) KDM4EALBOPRK1KCNH2RAB9A
SCHEMBL10120392 0.79 GABRA1 (0.39) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL6011806 0.78 KDM4E (0.52) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL6216568 0.78 KDM4E (0.52) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL4723542 0.78 TP53 (0.51) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL7998726 0.77 TP53 (0.56) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL6216380 0.76 KDM4E (0.50) GABRA1GABRB2KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539751-B1 PROCESS FOR THE PREPARATION OF IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDES SCINOPHARM TAIWAN LTD (TW) 2008-05-07 EP claimed
US-6861525-B2 Process for the preparation imidazo[1,2-A]pyridine-3-acetamides SCINOPHARM TAIWAN, LTD. (TW) 2005-03-01 US claimed
US-20040010146-A1 Process for the preparation imidazo[1,2-A]pyridine-3-acetamides SCINOPHARM TAIWAN, LTD. 2004-01-15 US claimed
CN-114249723-B Preparation method of zolpidem and key intermediate thereof 鲁南制药集团股份有限公司 2025-02-07 CN disclosed
CN-114249723-A Preparation method of zolpidem and key intermediate thereof 鲁南制药集团股份有限公司 2022-03-29 CN disclosed
US-8101633-B2 Preparation and utility of substituted imidazopyridine compounds with hypnotic effects AUSPEX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-7772248-B2 Preparation and utility of substituted imidazopyridine compounds with hypnotic effects AUSPEX PHARMACEUTICALS, INC. (US) 2010-08-10 US disclosed
US-20100121067-A1 PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100105720-A1 PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS AUSPEX PHARMACEUTICALS, INC. (US) 2010-04-29 US disclosed
EP-1809627-B1 SYNTHESIS OF HETEROARYL ACETAMIDES FROM REACTION MIXTURES HAVING REDUCED WATER CONTENT MALLINCKRODT INC (US) 2009-12-09 EP disclosed
US-7498439-B2 Synthesis of heteroaryl acetamides from reaction mixtures having reduced water content MALLINCKRODT INC. (US) 2009-03-03 US disclosed
EP-1575952-B1 SYNTHESIS OF HETEROARYL ACETAMIDES MALLINCKRODT INC (US) 2009-02-18 EP disclosed
US-7385056-B2 Synthesis of heteroaryl acetamides MALLINCKRODT INC. (US) 2008-06-10 US disclosed
US-7385056-B2 Synthesis of heteroaryl acetamides MALLINCKRODT INC. (US) 2008-06-10 US disclosed
EP-1539751-B1 PROCESS FOR THE PREPARATION OF IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDES SCINOPHARM TAIWAN LTD (TW) 2008-05-07 EP disclosed
US-20070281965-A1 PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS AUSPEX PHARMACEUTICALS, INC. (US) 2007-12-06 US disclosed
US-20070213537-A1 Synthesis Of Heteroaryl Acetamides From Reaction Mixtures Having Reduced Water Content MALLINCKRODT INC. 2007-09-13 US disclosed
US-6861525-B2 Process for the preparation imidazo[1,2-A]pyridine-3-acetamides SCINOPHARM TAIWAN, LTD. (TW) 2005-03-01 US disclosed
US-20040010146-A1 Process for the preparation imidazo[1,2-A]pyridine-3-acetamides SCINOPHARM TAIWAN, LTD. 2004-01-15 US disclosed
US-4794185-A TREATING CORRESPONDING CHLORO COMPOUND WITH REDUCING AGENT SYNTHELABO (FR) 1988-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121067-A1 PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS GABRA4, GABRP, GABBR1 GABRA1 6/4885GABRB2 17/4885KDM4E 695/4885
US-20070281965-A1 PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS GABRA4, GABRP, GABBR1 GABRA1 6/4885GABRB2 17/4885KDM4E 695/4885
US-20100105720-A1 PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS GABRA4, GABRP, GABBR1 GABRA1 6/4885GABRB2 17/4885KDM4E 695/4885
US-20070213537-A1 Synthesis Of Heteroaryl Acetamides From Reaction Mixtures Having Reduced Water Content SQSTM1, CYP3A43, HTR2A GABRA1 229/4885GABRB2 869/4885KDM4E 2530/4885
US-20040010146-A1 Process for the preparation imidazo[1,2-A]pyridine-3-acetamides AAK1, ACP3, AP2M1 GABRA1 332/4885GABRB2 1128/4885KDM4E 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.